Search
  1. Home
  2. Southern Africa
  3. South Africa
  • News

AIDS drug tender short list revealed

    JOHANNESBURG

    Pharmaceutical firms short-listed for South Africa's lucrative anti-AIDS drug tender have until the end of the week to submit their quotes.

    According to a local newspaper, Business Day, independent pharmaceutical industry sources spilled the beans by naming the companies, which until now had been kept secret by the government.

    During the three-year tender the manufacturers are expected to supply anti-AIDS drugs for the treatment of about 102,000 people in year one, increasing to about 180,000 by year three.

    The short-listed companies are Abbot, Aspen Pharmacare, Boehringer Ingelheim, Bristol Meyers Squibb, CiplaMedpro, Enaleni, GlaxoSmithKline, MSD, the South African subsidiary of Merck Sharpe Dohme, Pharma Marketing International, and Thembalami, the joint venture between Adcock Ingram and Indian pharmaceutical giant Ranbaxy.

    This article was produced by IRIN News while it was part of the United Nations Office for the Coordination of Humanitarian Affairs. Please send queries on copyright or liability to the UN. For more information: https://shop.un.org/rights-permissions

    Share this article

    Our ability to deliver compelling, field-based reporting on humanitarian crises rests on a few key principles: deep expertise, an unwavering commitment to amplifying affected voices, and a belief in the power of independent journalism to drive real change.

    We need your help to sustain and expand our work. Your donation will support our unique approach to journalism, helping fund everything from field-based investigations to the innovative storytelling that ensures marginalised voices are heard.

    Please consider joining our membership programme. Together, we can continue to make a meaningful impact on how the world responds to crises.

    Become a member of The New Humanitarian

    Support our journalism and become more involved in our community. Help us deliver informative, accessible, independent journalism that you can trust and provides accountability to the millions of people affected by crises worldwide.

    Join